# Esperto Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/esperto-medical

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.esperto.health
- Latest round: Series A (Feb 18, 2025)
- Investors on record: 6

## About

Esperto Medical, Inc. focuses on developing innovative non-invasive vital sign monitoring technology, enhancing patient care through its advanced product offerings. Esperto Medical, Inc. was founded in 2018 in the United States and specializes in non-invasive vital sign monitoring technology. The company has made a strategic pivot towards developing its flagship product, Resonance Sonomanometry, which employs sound waves for accurate vital sign measurement. In February 2025, Esperto Medical, Inc. raised series A funding co-led by Catalyst Health Ventures and BOLD Capital Partners, with participation from Wavemaker Three-Sixty Health, Freeflow Ventures, CalTech, and Maverick Ventures. Esperto Medical specializes in the development of non-invasive vital sign monitoring technology, primarily through its flagship product, Resonance Sonomanometry (RSM). This patented technology utilizes sound waves to measure vital signs with high accuracy, operating thousands of times per second without the need for calibration or traditional cuff-based methods. RSM provides continuous blood pressure readings, which are critical for effective vital sign monitoring in both clinical and home environments. The technology targets a wide range of end-users, including healthcare providers in hospitals and clinics, as well as individual patients seeking at-home monitoring solutions. The company's offerings are designed to be accessible globally, although specific geographical markets have not been detailed in the provided information. Esperto Medical has not yet commercialized its products; therefore, explicit revenue figures or transaction structures have not been disclosed. The company aims to establish partnerships within the healthcare sector, potentially engaging in business-to-business (B2B) transactions with hospitals and clinics, as well as direct sales to consumers for personal health monitoring. Transactions may involve service agreements or subscriptions for ongoing access to technology and updates, particularly considering the continuous monitoring aspect of the RSM technology. Given the innovative nature of their offerings, pricing plans will likely reflect the advanced capabilities of the RSM system, although specific pricing details for these services have not been disclosed. In February 2025, Esperto Medical, Inc. raised Series A funding co-led by Catalyst Health Ventures and BOLD Capital Partners, with participation from Wavemaker Three-Sixty Health, Freeflow Ventures, CalTech, and Maverick Ventures. The company will use the funding to support the development of its product and the testing process of its technology called Resonance Sonomanometry. Future strategies include the launch of new products that enhance monitoring capabilities, alongside plans to expand into targeted markets, although specific regions have not been mentioned. The funding will facilitate these initiatives, ensuring the continued evolution of their non-invasive monitoring technology.

## Funding rounds

- Series A, Feb 18, 2025 — Catalyst Health Ventures, Maverick Ventures Israel, CalTech, BOLD Capital Partners, Wavemaker Three-Sixty Health, Freeflow Ventures

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series A
- Maverick Ventures Israel (https://capitalatlas.ai/funds/maverick-ventures-israel) — Series A
- CalTech (https://capitalatlas.ai/funds/caltech) — Series A
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A
- Wavemaker Three-Sixty Health (https://capitalatlas.ai/funds/wavemaker-three-sixty-health) — Series A
- Freeflow Ventures (https://capitalatlas.ai/funds/freeflow-ventures) — Series A